Higher Circulating Visfatin Levels Are Associated With Increased Risk Of Atrial Fibrillation And Major Adverse Cardiovascular Events In Patients With Acute St-Elevation Myocardial Infarction

Heng-Jing Hu,Jie Qiu,Jia-Bing Huang,Qi-Ming Liu,Zhi-Han Tang,Shun-Lin Qu,Zhi-Sheng Jiang
2017-01-01
Abstract:Background: Circulating visfatin levels has reflected the long-term survival in patients with ST-elevation myocardial infarction myocardial infarction (STEMI). We postulated that higher visfatin would be linked to increased risk for atrial fibrillation (AF) and major adverse cardiovascular events (MACEs) in patients with STEMI treated with primary percutaneous coronary intervention (PPCI). Methods: Of the 604 patients with acute STEMI underwent the PPCI were enrolled in the study. ELISA was used to measure plasma visfatin concentrations. One-year MACEs and adverse events, were compared between patients with and without new-onset AF after PPCI, and using statistical analyses to respectively analyze the relationship between plasma visfatin level and MACEs, plasma visfatin level and new-onset AF. Results: Of the 604 patients, new-onset AF developed in 42 (6.95%). Compared with patients without AF after PPCI, patients with new-onset AF had higher 1-year rates of MACEs (30.95% vs 18.15%, P< 0.05). Moreover, compared with patients with low plasma visfatin levels (visfatin = 14.5 ng/ml), patients with higher plasma visfatin levels (visfatin <= 14.5 ng/ml) had higher 1-year rates of MACEs (26.50% vs 9.92%, P< 0.001) and newonset AF (10.24% vs 2.94%, P< 0.001). Analysis with multivariate Cox hazard regression model revealed that the independent predictors for the occurrence of new-onset AF were plasma visfatin level (hazard ratio [ HR] 1.51, 95% confidence interval [ CI] 1.03 to 2.23, P= 0.021) at 1 year. Conclusion: Plasma visfatin levels have a positive correlation with AF and MACEs in patients with acute STEMI treated with PPCI.
What problem does this paper attempt to address?